Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia

Pu Zhang, Lindsey Brinton, PhD, James S. Blachly, MD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2019) 134 (Supplement_1): 2072.

https://doi.org/10.1182/blood-2019-129036

Published: 2019

Journal Articles

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Fiona Brown, BS, Yang Zhang, PhD, Claire Hinterschied, Alexander Prouty, BS, Shelby Sloan, BS, JoBeth Helmig-Mason, Msc, Ji Hyun Chung, PhD, Kris Vaddi, PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Lapo Alinari, MD PhD, Peggy Scherle, PhD, Rosa Lapalombella, PhD, Jihye Paik, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 302.

https://doi.org/10.1182/blood-2019-130797

Published: 2019

Journal Articles

Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq

Caner Saygin, MD, Arletta Lozanski, Tzyy-Jye Doong, Shelley Orwick, BS, Deedra Nicolet, MS, Jadwiga Labanowska, Nyla A. Heerema, PhD, Rosa Lapalombella, PhD, Gregory K. Behbehani, MD PhD, John C. Byrd, MD, Gerard Lozanski, MD, James S. Blachly, MD

Blood (2019) 134 (Supplement_1): 186.

https://doi.org/10.1182/blood-2019-125285

Published: 2019

Journal Articles

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

Deborah M. Stephens, DO, Ying Huang, MS, MA, Akwasi Agyeman, Amy S. Ruppert, MAS, PhD, Boyu Hu, MD, Natalie Turner, APRN, Renee Vadeboncoeur, MSN, APRN, Kerry A Rogers, MD, Seema A. Bhat, MD, Basem M. William, MRCP,MD, Samantha Jaglowski, MDMPH, Hank Lockman, Martha Glenn, MD, Rosa Lapalombella, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 4310.

https://doi.org/10.1182/blood-2019-124544

Published: 2019

Journal Articles

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Shelby Sloan, BS, Fiona Brown, BS, JI Hyun Chung, PhD, Alexander Prouty, BS, Esther Wheeler, BS, Bonnie K Harrington, DVM, PhD, Eric Brooks, BS, Ayse S Yilmaz, MS, Hatice G Ozer, PhD, John C. Byrd, MD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Rosa Lapalombella, PhD, Kris Vaddi, PhD, Peggy Scherle, PhD, Youssef Youssef, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4065.

https://doi.org/10.1182/blood-2019-128998

Published: 2019

Journal Articles

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

Janani Ravikrishnan, Tzung-Huei Lai, PhD DVM, Elizabeth Muhowski, Lindsey Brinton, PhD, Katie Williams, MS, Alexandria Thompson, James S. Blachly, MD, Hatice Gulcin Ozer, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD, Jennifer Woyach, MD, Deepa Sampath, PhD

Blood (2019) 134 (Supplement_1): 2526.

https://doi.org/10.1182/blood-2019-128574

Published: 2019

Journal Articles

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

JI Hyun Chung, PhD, Shelby Sloan, BS, Peggy Scherle, PhD, Kris Vaddi, PhD, Said Sif, PhD, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 2777.

https://doi.org/10.1182/blood-2019-131020

Published: 2019

Journal Articles

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

Shaneice Renee Mitchell, BS, Nicole Grieselhuber, MD PhD, Yerdanos Asemelash, Matthew Cannon, BA, Shelley Orwick, BS, Pratibha Sharma, PhD, Virginia Goettl, DVM, PhD, Vinay K Puduvalli, MD MBBS, Deepa Sampath, PhD, Alice S. Mims, MD, James S. Blachly, MD, Amy M. Lehman, PhD, Bonnie K. Harrington, DVM, Justin Breitbach, Erkan Baloglu, William Senapedis, PhD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 3931.

https://doi.org/10.1182/blood-2018-99-119358

Published: 2018

Journal Articles

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

Janani Ravikrishnan, BS, Tzung-Huei Lai, PhD, Shaneice Renee Mitchell, BS, Pei-Jung Wu, BS, Shelley Orwick, BS, Chaomei Liu, PhD, Jennifer A. Woyach, MD, Alice S. Mims, MD, William Plunkett, PhD, Vinay K Puduvalli, MD MBBS, John C. Byrd, MD, Rosa Lapalombella, PhD, Deepa Sampath, PhD

Blood (2018) 132 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2018-99-116485

Published: 2018

Journal Articles

High-Throughput Mirna Analysis Suggests Pro-Inflammatory Profile in Sickle Cell Disease

Matthew Cannon, BA, Sarah Glass, Sidney Smith, Melanie Heinlein, Rosa Lapalombella, PhD, Payal C Desai, MD

Blood (2018) 132 (Supplement 1): 1077.

https://doi.org/10.1182/blood-2018-99-110812

Published: 2018

Journal Articles

PRMT5 Initiates an Epigenetic Program That Promotes Progression of Chronic Lymphocytic Leukemia

Zachary A Hing, BS, Jordan N. Skinner, B.S., Larry P. Beaver, Tzung-Huei Lai, PhD, Casey B. Cempre, B.S., Bonnie K. Harrington, DVM, Deepa Sampath, PhD, Amy M. Lehman, PhD, Lianbo Yu, PhD, Lapo Alinari, MD PhD, John C. Byrd, MD, Robert A Baiocchi, MD PhD, Rosa Lapalombella, PhD

Blood (2017) 130 (Supplement 1): 2487.

https://doi.org/10.1182/blood.V130.Suppl_1.2487.2487

Published: 2017

Journal Articles

Exploring the Role of the Recurrent Exportin 1 (XPO1/CRM1) Mutations E571G and E571K in Chronic Lymphocytic Leukemia

Zachary A. Hing, BS, James S. Blachly, MD, Virginia M. Goettl, DVM, PhD, Guramrit Singh, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2016) 128 (22): 972.

https://doi.org/10.1182/blood.V128.22.972.972

Published: 2016

Journal Articles

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

Nicole R. Grieselhuber, MD PhD, Shaneice R. Mitchell, BS, Shelley Orwick, BS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Sumithra Vasu, MBBS, William Blum, MD, James S. Blachly, MD, David M. Lucas, PhD, Ramiro Garzon, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3941.

https://doi.org/10.1182/blood.V128.22.3941.3941

Published: 2016

Journal Articles

Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression

Lara Rizzotto, PhD, Arianna Bottoni, PhD, Tzung-Huei Lai, PhD, Chaomei Liu, BS, Pearlly S Yan, PhD, Hatice G Ozer, PhD, Rosa Lapalombella, PhD, Jennifer A. Woyach, MD, Christopher C Oakes, PhD, James S. Blachly, MD, Deepa Sampath, PhD

Blood (2016) 128 (22): 2705.

https://doi.org/10.1182/blood.V128.22.2705.2705

Published: 2016

Journal Articles

BET Bromodomain Inhibition Selectively Targets the Epstein-Barr Virus Oncogene LMP1 While Promoting Virus-Specific, Adaptive Anti-Tumor Activity

Emily Smith, Andrew Stiff, BS, John T. Patton, PhD, William Carson, III, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2016) 128 (22): 46.

https://doi.org/10.1182/blood.V128.22.46.46

Published: 2016

Journal Articles

PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas

Porsha L. Smith, PhD, Fengting Yan, MD PhD, John T. Patton, PhD, Lapo Alinari, MD PhD, Vrajesh Karkhanis, PhD, Leona Ayers, MD, Natarajan Muthusamy, DVM, PhD, Anjali Mishra, PhD, Elshafa Ahmed, DVM, Said Sif, PhD, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2016) 128 (22): 2936.

https://doi.org/10.1182/blood.V128.22.2936.2936

Published: 2016

Journal Articles

The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Kerry A. Rogers, MD, Dalia El-Gamal, PhD, Harrington K. Bonnie, DVM, Hing A. Zachary, BS, Goettl M. Virginia, DVM, PhD, Mantel Rose, Lisa L. Smith, MS, Lianbo Yu, PhD, Amy J. Johnson, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD, Jennifer A. Woyach, MD

Blood (2015) 126 (23): 2752.

https://doi.org/10.1182/blood.V126.23.2752.2752

Published: 2015

Journal Articles

Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia

Arianna Bottoni, Rizzotto Lara, PhD, Lai Tzung-Huei, PhD, Rose Mantel, Lisa Simith, Dalia El-Gamal, PhD, Amy J. Johnson, PhD, Rosa Lapalombella, PhD, James S. Blachly, MD, John C. Byrd, MD, Jennifer A. Woyach, MD, Deepa Sampath, PhD

Blood (2015) 126 (23): 1232.

https://doi.org/10.1182/blood.V126.23.1232.1232

Published: 2015

Journal Articles

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

Blood (2015) 126 (23): 317.

https://doi.org/10.1182/blood.V126.23.317.317

Published: 2015

Journal Articles

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

Dalia El-Gamal, PhD, Zachary A. Hing, BS, Shaneice Mitchell, BS, Taylor D. LaFollette, Paul J. Brennan, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD MPH, Farrukh Awan, MD MS, Leslie A. Andritsos, MD, James S. Blachly, MD, Katie Williams, MS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Jennifer A. Woyach, MD, Amy M. Lehman, MAS, Lianbo Yu, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2015) 126 (23): 318.

https://doi.org/10.1182/blood.V126.23.318.318

Published: 2015

NARROW

Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

High-Throughput Mirna Analysis Suggests Pro-Inflammatory Profile in Sickle Cell Disease

PRMT5 Initiates an Epigenetic Program That Promotes Progression of Chronic Lymphocytic Leukemia

Exploring the Role of the Recurrent Exportin 1 (XPO1/CRM1) Mutations E571G and E571K in Chronic Lymphocytic Leukemia

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression

BET Bromodomain Inhibition Selectively Targets the Epstein-Barr Virus Oncogene LMP1 While Promoting Virus-Specific, Adaptive Anti-Tumor Activity

PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas

The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only